SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

VTVT

vTv Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 11h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The next major catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Monitor cash runway updates and any partnering discussions for HPPD, which could provide non-dilutive funding.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

VTVT drug pipeline →

cadisegliatin

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$21.03
T+0 close · Nov 5, 2026 · via day close
Latest settled
−6.37%
T+5 · $19.69 · next T+20 in 20d
Vs SPY
−8.97%
α at T+5
Latest observation
−15.83%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $21.03entry
  2. T+1 · 8d ago +0.71%α −1.65% · $21.18
  3. T+5 · 4d ago −6.37%α −8.97% · $19.69
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

vTv Therapeutics reported a Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss a year ago, with zero revenue. The key event is the completion of enrollment in the Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes, with topline results expected in mid 2027. The company has $77.2M in cash, which it expects to fund operations through that readout.

Key Financial Metrics

EPS
−$0.94
Revenue
$0.00
est $0.00

Key Facts

  • Phase 3 CATT1 trial enrollment completed with 166 participants randomized; topline results expected mid 2027
  • Cash and cash equivalents $77.2M as of September 30, 2026, down from $88.9M at December 31, 2025
  • Net loss attributable to vTv shareholders was $11.6M ($0.94 per share) for Q3 2026 vs $8.7M ($1.08 per share) for Q3 2025
  • R&D expenses $7.5M in Q3 2026 vs $7.0M in Q3 2025, driven by Phase 3 CATT1 investment
  • FDA granted Orphan Drug Designation to HPPD for sickle cell disease in October 2026
  • First participant randomized in Phase 2a Hybrid CATT1 pilot study for cadisegliatin in hybrid closed-loop insulin delivery systems

Financial Impact

Cash burn of ~$11.7M from Dec 2025 to Sep 2026; net loss of $11.6M in Q3 2026

cashnet lossR&D expenses

Risk Factors

  • Phase 3 CATT1 trial may fail to meet primary endpoint, wiping out the lead pipeline asset
  • Cash burn rate may require additional financing before mid 2027 if expenses increase or timelines slip
  • Zero revenue; fully dependent on clinical trial success and potential partnerships

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397006

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026